New Clinical Data Highlights Onera Health’s Patch-Based Home Polysomnography Solution at SLEEP 2025
Onera Health, a leader in transforming remote sleep diagnostics and monitoring, has today announced that its patient-applied patch-based home Polysomnography Solution will be prominently featured in multiple scientific presentations at the forthcoming SLEEP 2025 conference. The MedTech company will showcase this innovative solution at booth #1145 during the largest annual conference, which brings together leading experts and innovators in the field of sleep medicine. Furthermore, Onera Health will host a symposium on "Advancing Access to PSG" on Monday, June 9.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250604390799/en/
A female patient is sleeping while undergoing a sleep study with Onera Health's home Polysomnography solution.
The 39th annual meeting of the Associated Professional Sleep Societies (APSS) will present the latest clinical data and insights that promise to reshape the landscape of sleep medicine. This year's conference will take place from June 8 to 11, 2025, in Seattle, Washington.
“We are excited to see our Patch-based Type II Polysomnography System highlighted in four different presentations and to be an integral part of the evolving field of sleep medicine by advancing access to the gold standard of PSG sleep testing,” states Ruben de Francisco, Founder and CEO of Onera Health.
The clinical utility of the Onera home PSG system will be presented in four poster presentations. Details of the presentations are as follows:
Title: Assessment of Disease Burden in PAP-Intolerant OSA Patients Using Home Polysomnography: A Pilot Study
Authors: Heiser C et al.
Poster Board Number: #219
Poster Presentation Date and Time: June 9, 2025, 10:00 - 11:45 am
Abstract ID: 661
Title: Signal Quality and Recording Characteristics of Patient-Applied Home Polysomnography: A Real-World Analysis Across US and European Settings
Authors: Dimitrov T et al.
Poster Board Number: #543
Poster Presentation Date and Time: June 10, 2025, 11:00 - 11:45 am
Abstract ID: 1666
Title: Validation of a Novel Patch-Based Type II Polysomnography System
Authors: Schneider H et al.
Poster Board Number: #319
Poster Presentation Date and Time: June 11, 2025, 10:00 - 11:45 am
Abstract ID: 677
Title: Patient Perception of a Novel Patch-Based Type II Polysomnography System
Authors: Schneider H et al.
Poster Board Number: #320
Poster Presentation Date and Time: June 11, 2025, 10:00 - 11:45 am
Abstract ID: 678
Additional presentations by experts from leading institutions will feature validation results, insights from real-world implementation, and the clinical implications of home PSG testing during a symposium titled "Expanding Access, Enhancing Outcomes: The Future of Sleep Diagnostics with Home Polysomnography," which will be hosted by Onera Health on June 9.
“Home polysomnography addresses significant challenges, including the shortage of in-laboratory beds, technicians, and sleep physicians. This shortage has led to escalating costs and an increasing unmet clinical demand, with many patients suffering from sleep disorders remaining undiagnosed. This symposium aims to provide valuable insights into how hPSG can enhance patient care pathways and is already beginning to reshape the landscape of sleep healthcare by broadening access to gold standard PSG testing. I am confident that it will foster engaging discussions with esteemed panelists regarding the emerging opportunities for remote sleep diagnostics and care,” explains Ruben de Francisco.
Attendees can anticipate the following presentations:
- David P. White, MD, part-time Professor of Medicine at Harvard Medical School – "The Perfect Storm: Why Sleep Medicine Needs to Transform Now"
- Thomas Penzel, PhD, Charité University Hospital Berlin – "Home Polysomnography Comes of Age: Validation Study Results"
- Anupamjeet Kaur Sekhon, MD, Kaiser Permanente Fontana Medical Center– "From Lab to Home: Implementing Home Sleep Testing at Scale"
About Onera Health
Onera Health is a leader in transforming sleep medicine and remote monitoring. Their breakthrough diagnostic solutions and services are poised to help millions of people struggling with sleep-related ailments while also impacting other medical fields by monitoring various chronic conditions, ultimately improving the health and quality of life of patients worldwide. The company’s innovative solutions provide comprehensive sleep test data to physicians in a variety of clinical and non-clinical environments to optimize patient care and reduce healthcare costs. Onera has offices in the Netherlands and the United States. For further information, please visit onerahealth.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250604390799/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vertex Presents New Data on Benefits of ALYFTREK® and Importance of Achieving Lower Sweat Chloride Levels at the European Cystic Fibrosis Conference6.6.2025 18:00:00 CEST | Press release
- Oral presentation on outcomes following treatment with CFTR modulators show that improvements in CFTR function, as measured by lower sweat chloride, correlate with better outcomes for people with cystic fibrosis - - Oral presentation on new post hoc data from randomized, controlled and open-label trials suggest improved quality of life results with ALYFTREK compared to TRIKAFTA® – Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data across multiple studies demonstrating positive clinical and quality of life benefits of treatment with CFTR modulators and, in particular, ALYFTREK® (vanzacaftor/tezacaftor/deutivacaftor), which is approved in the United States and United Kingdom and is currently under review with health authorities in the EU, Canada, Australia, New Zealand and Switzerland. These data were presented at this year’s European Cystic Fibrosis Society’s (ECFS) 48th European Cystic Fibrosis Conference held June 4-7, 2025, in Milan, Italy. During the conferenc
Andersen Consulting tilføjer dimension med David and Golyat6.6.2025 16:33:00 CEST | Pressemeddelelse
Andersen Consulting udbygger sin globale konsulentkapacitet gennem en samarbejdsaftale med David and Golyat, en filippinsk konsulentvirksomhed inden for digital strategi. Med et stærkt fokus på business intelligence, kundeindsigt og digital first-eksekvering arbejder David and Golyat med kunder på tværs af flere sektorer – herunder regeringer, udviklingsorganisationer og private virksomheder – for at skabe langsigtet værdi gennem datainformerede beslutninger. Miko David, administrerende partner i David and Golyat, siger: "Vi ser frem til samarbejdet med Andersen Consulting, da det er en milepæl i vores vækstforløb. Ved at kombinere vores ekspertise inden for digital strategi og Andersen Consultings globale platform er vi i stand til at levere endnu større værdi til kunder, der navigerer på komplekse markeder." "Dette samarbejde betyder, at vi kan tilføre en ekstra dimension til vores globale konsulentplatform," siger Mark L. Vorsatz, global bestyrelsesformand og administrerende direktø
IBSA Derma at IMCAS Asia 2025: spotlight on the future of aesthetic medicine in the 10th Anniversary Year of NAHYCO® Technology6.6.2025 16:00:00 CEST | Press release
IBSA Derma, the dermoaesthetic division of Swiss company IBSA, will participate in the 18th IMCAS Asia Congress in Bangkok, gathering over 3,000 professionals from across the region to explore the future of aesthetic and regenerative medicine.With the presence in the Congress and a dedicated scientific symposium, the company reaffirms its commitment to advancing bioremodeling approaches and promoting a holistic, science-driven vision of authentic beauty.This year marks a key milestone for IBSA Derma: 10 years of NAHYCO® Technology, a patented innovation in hyaluronic acid science that continues to shape the future of tissue regeneration. IBSA Derma – the dermoaesthetic division of IBSA – once again confirms its leadership in the international aesthetic medicine landscape by participating in the 18th edition of IMCAS Asia, taking place from June 6 to 8 in Bangkok, Thailand. With over 3,000 attendees expected, the event represents a key opportunity for physicians and experts to share the
HistoSonics Completes Enrollment in #HOPE4KIDNEY Trial Evaluating Non-Invasive Histotripsy to Treat Kidney Tumors6.6.2025 14:00:00 CEST | Press release
Pivotal Study Advances to Establish Histotripsy as a Non-Thermal, Surgery-Free Alternative to Destroy and Liquefy Kidney Tumors HistoSonics, Inc., the manufacturer of the Edison® Histotripsy System and novel histotripsy therapy platforms, today announced the completion of patient enrollment in its pivotal #HOPE4KIDNEY trial. This prospective, multi-center, single-arm trial is designed to evaluate the safety and effectiveness of the Edison System in destroying kidney tissue by treating primary solid kidney tumors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250606659747/en/ Edison Histotripsy System Procedure for Kidney Tumor Animation The trial enrolled patients with a single, non-metastatic solid kidney mass ≤3 cm, confirmed by imaging and biopsy. Subjects will be followed for five years post-procedure, with evaluations at multiple time points, including 14-day, 30-day, 90-day, 180-day, and annual assessments. The Edison
Norwegian Tech Firm Builds Military Command Center in 24 Hours6.6.2025 13:45:00 CEST | Press release
Norwegian technology provider Cyviz has successfully developed a fully mobile and ballistic-proof command center - designed, configured, and made operational in just 24 hours. The solution was showcased during a military exercise led by the Dutch Ministry of Defence and has already sparked interest from NATO members and civil protection agencies across Europe. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250606640770/en/ Cyviz demonstrates rapid deployment capability with a mobile, container-based control room for defense and crisis response Cyviz and its partners constructed the command room inside a 14-ton container designed for transport on standard military vehicles and resistant to machine gun fire. The unit was deployed at a military base in the Netherlands, where Cyviz was tasked with delivering a fully functional command-and-control environment, under strict time constraints and in a high-stakes simulation. "You do
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom